Bolton Medical, a subsidiary of Spanish laboratory equipment supplier WerfenLife, has obtained CE Mark approval for the Treo abdominal stent graft system, which will be used to treat abdominal aortic aneurysms (AAAs).
Treo, the latest advancement in endovascular aneurysm repair (EVAR), features enhanced technology that helps physicians to provide better AAA treatment for patients.
Designed as a three-piece system, the system is available in a range of sizes to allow precise treatment and greater patient applicability.
Treo is claimed to be the only EVAR solution with dual proximal fixation and clasping mechanism, and is designed for accurate and controlled deployment, offering long-term stability of the stent graft.
Bolton Medical research and development vice-president Scott Rush said: "We believe that in EVAR, the tri-modular strategy is the best approach.
"This is because it allows you to deliver a tailored solution to each patient by selecting specific components to precisely work in that individual anatomy."
In October, the company intends to start a limited market release of the abdominal stent graft system with selected customers in Europe.
Carolina Vascular surgeon John Henretta said: "Stent migration and endoleaks are major concerns in EVAR.
"The Treo stent graft offers both suprarenal and infrarenal fixation, distributing the attachment points in two different anatomical levels, which may work to reduce potential endoleaks, particularly in angulated necks."
Bolton Medical will officially launch Treo at the Leipzig Interventional Course in January 2016.
Bolton Medical CEO Paul Kuznik said: "We will showcase the technology with deployment demonstrations at our booth, expert panel discussions and live case presentations."
Bolton is involved in developing products and technology focused on the aorta, while WerfenLife produces and distributes medical diagnostic solutions and medical devices worldwide.